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Abstract 
 
Opioid analgesics are increasingly used to alleviate severe acute and chronic pain.  
Opioid Induced Constipation (OIC) is the most common side effect of opioid 
analgesia which can have a significant effect on the persons’ quality of life and lead 
some to decrease or stop taking their analgesia. Although it is recommended that 
laxative therapy is commenced at the same time as opioid medication, many 
laxatives do not target the underlying cause of OIC and therefore may be ineffective. 
As with any patient with constipation other causes should be identified and where 
possible modified to reduce the risk of OIC. Simple laxatives remain the first line 
treatment, but there efficacy should be regularly reviewed. Newer opioid antagonist 
medication should be considered where these are simple laxatives are ineffective.  
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Introduction 
 
Opioids are a major class of analgesics including tramadol, oxycodone and codeine, 
which are increasingly used to alleviate severe acute and chronic pain, including non-
cancer and cancer pain (Moore et al, 2013).  Constipation is the most common side 
effect of opioid analgesia, with between 40-90% of patients developing opioid-
induced constipation (OIC) (Coyne et al, 2015). Guidelines therefore state that all 
patients should commence laxatives at the start of opioid therapy and continue 
throughout their treatment (National Institute for Health and Care Excellence, (NICE) 
2016 and British Medical Association and Royal Pharmaceutical Society, 2016 
(March)). Even when this practice is adhered to, around half of patients will not have 
the desired effect. Most laxatives do not target the underlying cause of OIC, and as 
such are ineffective. OIC can have a significant impact on quality of life and may 
provoke some patients to decrease of stop their opioid therapy to relieve the 
constipation. 
 
Prevalence of Opioid-Induced Constipation 
 
Around one third to one half of the UK population report chronic pain (Fayaz et al, 
2016) for which many are prescribed opioid analgesia (Moore et al., 2013). Around 
half of people admitted into palliative care are reported to experience constipation, 
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with approximately 80% requiring laxatives, especially those taking opioid 
medications (Fallon and O'Neill, 1998 and Sykes, 2013). The use of opioid analgesia, 
frequently results in gastrointestinal side effects, including constipation with 
estimates of OIC ranging between 40-60% of patients treated  with opioid for non-
cancer pain, even when laxtive medication is used (Coyne et al, 2015).  
 
 
Definition of constipation 
 
The term constipation refers to a decrease in the frequency and/or difficulty in 
passing bowel movements (straining), with the stool typically hard due to the 
reduced water content (Muller-Lissner and Wald, 2010). Constipation is a symptom 
not a disease (Blane and Blagrave, 2011). Normal bowel frequency varies, ranging 
from three bowel movements a day to three per week. Therefore constipation is 
usually diagnosed when there are fewer than three bowel movements a week (Gray, 
2011 and Higgins and Johanson, 2004).  Since the mechanism of opioid-induced 
constipation differs from that of functional constipation (Gaertner et al, 2014), the 
following consensus definition was proposed by Camilleri et al (2014): 
A change when initiating opioid therapy from baseline bowel habits that is 
characterized by any of the following: 
 reduced bowel movement frequency 
 development or worsening of straining to pass bowel movements 
 a sense of incomplete rectal evacuation 
 harder stool consistency 
 Neurological control of the bowel 
 The GI tract is controlled by the autonomic nervous system with sympathetic and 
parasympathetic nerves working together (Bajwa and Emmanuel, 2009 and 
Emmanuel, 2004). Sympathetic nerve innervation originates from the superior and 
inferior mesenteric nerves (spinal cord level T9–T12) and the hypogastric nerve 
(spinal cord level T11–L2). The hypogastric nerve sends out sympathetic innervation 
from the L1, L2, and L3 spinal segments to the lower colon, rectum, and sphincter, 
leading to relaxation of the rectum and anal canal (Emmanuel, 2004 and Bajwa and 
Emmanuel, 2009). The somatic pudendal nerve (S2–4) innervates the pelvic floor and 
the external anal sphincter. This nerve stimulates the rectum and anal canal to 
contract or tighten, causing the internal anal sphincter to relax and allowing faeces 
to pass through the anus, while the rectum and anal canal contract, assisting in 
defecation. The internal anal sphincter functions outside of conscious control, 
meaning that it operates in an automatic manner (Emmanuel, 2004; Bajwa and 
Emmanuel, 2009). The bowel also has an intrinsic nervous system (known as the 
enteric nervous system), composed of the submucosal (i.e. Meissner) and myenteric 
(i.e. Auerbach) plexuses, which largely regulate segment-to-segment movement of 
the GI tract (Bajwa and Emmanuel, 2009).  
 
How do opioid analgesics cause constipation? 
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Opioid receptors are an inhibitory group of G-protein-coupled receptors (GPCR) with 
opioids as ligands that sense molecules outside the cell, activating signal 
transduction pathways inside the cell which produce cellular responses (Camilleri  et 
al, 2014, Holzer, 2009 and Brock et al, 2012). Both the sympathetic and 
parasympathetic nervous systems are regulated by GPRC pathways. Centrally opioids 
antagonize four receptor subtypes:  (mu), δ (delta), К (Kappa) and ORL-1 (opioid 
receptor-like 1).   
Endogenous opioids are dynorhins, enkephalins, endorphins, endomorphins and 
nociception. In the intestine, met-enkephalin, leu-enkephalin, β-endorphin and 
dynorphin occur in both neurons and endocrine cells (Camilleri  et al, 2014 and Brock 
et al, 2012). 
 
Many opioids produce their analgesic effect by binding to () mu-opioid receptors in 
the central nervous system. However they also bind to these receptors peripherally 
in areas such as the gastrointestinal (GI) tract (Camilleri  et al, 2014, Holzer, 2009 and 
Brock et al, 2012). The GI tract is densely packed with mu-opioid receptors. When 
released, opioid peptides activate the opioid receptors on the enteric system that 
controls motility and secretion. OIC is therefore caused by mu-opioid receptor 
agonists binding to mu-receptors in the myenteric and submucosal plexus (Brock et 
al, 2012 and Sharma and Jamal, 2013) tissues within the GI tract, this leads to 
inhibition of the propulsive activity of the intestine and slower gut transit time. 
Additionally centrally acting opioids may reduce intestinal peristalsis. 
 
The high density of mu () receptors within the enteric system is thought to mediate 
most of the opioid gastrointestinal side effects including: 
 Reducing bowel tone and contractility, which reduces gut transit time. 
 Increased pyloric, anal and biliary sphincter tone. 
 Reduced enteric, biliary and pancreatic secretions. 
 Increased water absorption from the bowel, leading to hard small stool. 
 Reduced gastric emptying 
 Reduced propulsion of chime through the intestine. 
 
(Camilleri  et al, 2014, Holzer, 2009, Brock et al, 2012 and and Sharma and Jamal, 
2013) 
 
Assessment 
 
Many patients with constipation will not inform clinicians of their symptoms 
(Prichard., Norton and Bharucha, 2016). Therefore healthcare practitioners need to 
pro-actively ask patients receiving opioid medications at each opportunity if they are 
experiencing any symptoms. The first part of an assessment is to gain an overview of 
the patient’s current bowel habit. 
The Rome Foundation (Lacy et al, 2016) suggested the following questions to aid 
patients describe their bowel habits and to identify bowel dysfunction: 
 
 How frequently do you pass a bowel motion? 
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 How often are your stools lumpy or hard? 
 How often do you have to straining to pass a bowel motion? 
 How often do you feel that your bowel motion is incomplete? 
 How often do you feel a blockage in your anus when passing a bowel motion? 
 How often do you use manual manoeuvres to facilitate a bowel motion? 
       
Adapted from Lacy et al (2016) 
 
In addition to these questions, the Rome III criteria (Mostafa, 2008), is a 
standardised diagnostic tool for assessing chronic functional constipation.  Diagnosis 
is based on 2 or more of the following symptoms being present for at elaset 12 
weeks within the last 6 months: 
 
 Straining at defecation at least 25% of the time 
 Emptying stools that are lumpy/hard at least 25% of the time 
 Experiencing a sensation of incomplete evacuation at least 25% of the time 
 Having three or fewer bowel movements a week. 
 
However the Rome Foundation questions and the Rome III criteria (Mostafa, 2008) 
were developed for use with the general population and include criteria which are not 
simple to explain from a patients perspective, and as such may not be adequate for 
OIC (Ducrotte and Causse, 2012). The Bowel Function Index (BFI) was developed and 
validated specifically for OIC (Ducrotte and Causse, 2012). The BFI is a clinician 
administered three item questionnaire that assesses for constipation based on: 
 
 Ease of defecation during the last 7 days according to patient assessment 
 Feeling of incomplete evacuation during the last 7 days according to patient 
assessment 
 The patient's judgement of constipation during the last 7 days 
 
The score is expressed as an average between 0-100, with a higher score indicating 
more severe bowel dysfunction. A score of lower than 28.8 represents normal bowel 
function, with changes of at least 12 points representing a clinically meaningful 
difference.    
 
These tools should be used in conjunction with the Bristol stool chart (Heaton and 
Lewis, 1997) to aid patients describe their stool.  
 
Investigations are required when constipation cannot clearly be linked to opioid use or 
when OIC does not respond to laxatives (Pritchard., Norton and Bharucha, 2016). Any 
assessment should consider the patients clinical condition and may include a full blood 
count and sodium, calcium, potassium and thyroid stimulating hormone levels checked 
to exclude underlying pathology that can potentially be corrected (Bharucha., 
Pemberton, and Locke, 2013 and Clark et al, 2012).  
 
Treatment and management options 
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The primary aim of treatment and management of constipation is to promote a 
regular, predictable, and comfortable bowel movement for the patient. Any treatment 
programme should include modification of the person’s diet, fluid intake and lifestyle 
where possible. 
 
Before treating constipation any faecal impaction/loading should be relieved. A 
combination of oral laxatives and rectal interventions (enemas or suppositories) may 
be required initially to remove impaction (National Institute for Healthcare Excellence 
(NICE), 2014a) 
 
Since the effects of different opioids on the gastrointestinal (GI) system vary, for 
example although codiene, oxycodone and tapentadol can all cause constipation, 
only codiene leads to delayed colonic transit (Jeong et al, 2012 and Prichard., Norton 
and Bharucha, 2016). Only 46% of patients treated with opioids report desired 
treatment results with simple laxatives (Pappagalio, 2001). Therefore opioid 
antagonists which specifically inhibit the effect of opioids within the GItract may be 
more effective (Camilleri et al, 2014 and Thomas and Cooney, 2008).Current 
available opioid antagonists are naloxone (naloxegol), methylnatrexone bromide 
(British Medical Association and Royal Pharmaceutical Society, 2016 (March)). 
 
A step-wise approach is still advocated utilising simple laxatives as they are 
inexpensive and can be effective in the management and prevention of OIC 
(Prichard., Norton and Bharucha, 2016) . A regime should start with regularly 
administered osmotic agents (e,g, polyethylene glycol such as cosmocol, laxido or  
movicol), with the addition of a stimulant laxative such as senna on a as- required 
basis (Prichard., Norton and Bharucha, 2016). Where these are ineffective 
consideration should be given to commencing either Lubiprostine or Prucalopride 
(Prichard., Norton and Bharucha, 2016). Lubiprostine and Prucalopride are licensed 
for the treatment of chronic idiopathic constipation in adults, whose condition has 
not responded to lifestyle changes (National Institute for Health and Care Excellence 
(NICE), 2014b). NICE (2014a) define idiopathic chronic constipation as "adults for 
whom treatment with at least 2 laxatives from different classes, at the highest 
tolerated doses for at elast 6 months has failed to provide adequate relief and for 
whom Invasive treatment for constipation is being considered". An inadequate 
response is defined as opioid-induced constipation symptoms of at least moderate 
severity in at least 1 of the 4 stool symptom domains (that is, incomplete bowel 
movement, hard stools, straining or false alarms) while taking at least 1 laxative class 
for at least 4 days during the prior 2 weeks (NICE, 2014a and NICE, 2010). However, 
the efficacy of these drugs has not been demonstrated on OIC related cancer pain 
(Prichard., Norton and Bharucha, 2016).  
 
Prucalopirde 
 
Prucalopride is a selective, high affinity 5-HT₄ receptor agonist, which stimulates colonic 
mass movement, targeting the impaired motility that is associated with chronic 
constipation (Kumar., Barker and Emmanuel, 2014 ).  
5-HT₄ receptors (seratonin) are located in the alimentary canal and central nervous 
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system as well as the urinary bladder, heart and adrenal gland. Serotonin (5-HT) is a 
chemical that transmits signals to targets within the body and can affect gut motility 
and sensitivity. Seratonin also triggers reflexes that are crucial for the digestion of food 
and the elimination of waste products (Mawe and Hoffman, 2012). Prucalopride is an 
oral medication which is recommended by NICE (2010) for the "symptomatic relief of 
constipation  in women in whom laxatives fail to provide adequate relief". Prucalopride 
should only be prescribed by clinicians with experience of treating chronic idiopathic 
constipation and review of the patient’s previous laxative treatments. 
 
Lubipostone 
 
Lubiprostone is a ibicyclic fatty acid that activates the chloride channels of the 
gastrointestinal epithelial cells, producing a chloride rich fluid secretion. Chloride 
channels are key regulators in the intestinal tract, which transport chloride ions into the 
lumen with sodium and  fluids passively following, thus increasing intestinal fluid 
secretion (NICE, 2014b). These secretions soften the stool, Increase motility and 
promote bowel movements (Bajwa and Emmanuel, 2009).  
 
Currently available Opioid antagonists 
 
Naloxone 
Naloxone is a centrally and peripherally acting opioid antagonist, the effects of which 
are predominantly limited to the intestine, due to its high first pass metabolism 
(Meissner et al, 2000). Naloxone inhibits the stimulation of µ-opioid receptors within 
the GI tract (Chey et al, 2014). In patients with impaired liver function, the first-pass 
metabolism of naloxone is reduced and bioavailbility is increased. Naloxone can 
cross the blood brain barrier which may lead to opioid withdrawal and loss of 
analgesic effect (Burns., McWilliams and Ross, 2014). 
Naloxegol is a form of naloxone which has been pegylated (attached to a molecule of 
polyethylene glycol, or PEG), therefore reducing its ability to cross the blood-brain 
barrier (Burns., McWilliams and Ross, 2014 and Camilleri et al, 2014). In this form, it 
selectively antagonises peripheral opioid receptors to relieve constipation (NICE, 
2015).  
Methylynaltrexone bromide  
 
Methylynaltrexone bromide is a peripheral selective antagonist of the mu receptor. 
This is considered peripheral as it is unlikely to cross the blood brain barrier and does 
not act on the central nervous system. Indicated for opioid induced constipation in 
terminally ill patients (Camilleri et al, 2014). As methylynaltrexone bromide is only 
currently available in subcutaneous injection form, some patients may be reluctant 
to use this option. Methylynaltrexone bromide should only be used where trials of 
standard laxatives have failed. It has been demonstrated to be less effective for 
patients who have co-existent modifiable risk factors (Clark et al, 2012). 
7 
 
 
Conclusion 
 
Constipation is a common symptom for patients taking opioid analgesia, which may 
prevent adequate pain control. Patients should be proactively asked about 
symptoms of constipation and laxatives should be provided prophylactically when 
starting opioid medications in an effort to prevent OIC. As with any patient with 
constipation other causes should be identified and where possible modified to 
reduce the risk and impact of OIC. Simple laxatives remain the first line treatment 
option for patients with OIC however their effectiveness should be regularly 
reviewed, especially when modifying treatment regimens and increasing analgesic 
doses. Where newer types of laxatives are required their side effects should be 
monitored especially in relation to loss of analgesic efficacy.  
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